Multiply Labs Raises $75 Million Series B for Pharma Automation Robotics

Multiply Labs Inc. has raised $75 million in a Series B funding round, according to a report by SiliconANGLE. The investment was led by NantWorks, the venture capital arm of billionaire investor and surgeon Patrick Soon-Shiong. This latest capital infusion supports the startup’s ongoing development of automation equipment specifically designed for pharmaceutical manufacturers.

The $75 million injection highlights growing investor interest in robotics that streamline drug production. Multiply Labs focuses on building systems that automate complex pharmaceutical manufacturing processes. By integrating robotic technology into these facilities, the company aims to improve efficiency and consistency in drugmaking operations. This sector is increasingly critical as global demand for pharmaceuticals continues to rise.

Context and Background

Multiply Labs operates at the intersection of robotics and biopharmaceutical manufacturing. The startup develops specialized equipment that helps drugmakers automate their production lines. These systems are designed to handle the precise and regulated requirements of pharmaceutical environments. The company’s technology seeks to reduce manual labor and potential errors in drug creation.

Patrick Soon-Shiong’s NantWorks led the funding round, signaling strategic interest in health-tech innovation. Soon-Shiong is a prominent figure in both medicine and technology investment. His involvement suggests a focus on practical applications of robotics in healthcare supply chains. The funding allows Multiply Labs to scale its operations and expand its product offerings.

Who Is Affected

Pharmaceutical manufacturers are the primary beneficiaries of Multiply Labs’ technology. These companies face increasing pressure to produce drugs efficiently while maintaining strict quality controls. Automation can help address labor shortages and reduce production bottlenecks. The investment also impacts the broader robotics industry, demonstrating viability in regulated sectors.

Investors in the health-tech sector are closely watching this deal. The $75 million raise validates the market for industrial automation in pharma. Other startups in similar spaces may see increased competition or partnership opportunities. The move reflects a broader trend of capital flowing into specialized manufacturing technologies.

What should you do?

Security and technology professionals should monitor developments in industrial automation security. As pharmaceutical manufacturing becomes more automated, the attack surface for cyber threats expands. Organizations should assess how robotic systems integrate with existing IT infrastructure. Understanding the vendor’s security practices is crucial for risk management.

What to do and how to stay safe: Multiply Labs

• Review vendor security documentation for any new automation tools integrated into manufacturing environments
• Ensure network segmentation isolates robotic control systems from general corporate IT networks
• Monitor for updates or security advisories related to the specific automation platforms in use
• Verify that access controls for physical and digital interfaces with manufacturing equipment are strictly enforced

General security guidance from the Threat Times newsroom. It is not confirmed advice from the organisations named in this story.

Frequently asked questions

How much funding did Multiply Labs raise?

Multiply Labs raised $75 million in its Series B funding round.

Who led the Series B funding round?

The round was led by NantWorks, the venture capital firm associated with Patrick Soon-Shiong.

What does Multiply Labs do?

The company develops robotic systems and automation equipment for pharmaceutical manufacturing processes.